Compared to the general population, patients with a confirmed BRCA1or BRCA2 mutation are at greater risk of developing cancer during their lifetime. Women have up to an 85% risk of breast cancer and up to a 40% risk of ovarian cancer. Men also have up to a 7% risk for prostate, breast and other cancers. Their children, siblings and parents face a 50% chance of having the same autosomal dominant mutation.
Valuable genetic information can empower physicians and patients to help shape patient management. There’s a need to know if a BRCA mutation is present, because proactive steps can be taken to mitigate the risk of cancer for patient and family members both today and tomorrow.
Please contact your MACL representative for more information on our BRCA offerings;
91863 BRCAvantage – Comprehensive
91864 BRCAvantage Ashkenazi Jewish Screen
91865 BRCAvantage Single Site
91866 BRCAvantage Rearrangements
92587 BRCAvantage Plus
Mid America Clinical Laboratories can provide:
fast, economical testing to provide answers needed for making important treatment decisions. Pre-Authorization support streamlines the process and eases the workload.